This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ferrara, N. Search for Related Content PubMed PubMed Citation Articles by Ferrara, N.

Vascular Endothelial Growth Factor as a Target for Anticancer Therapy

Genentech, Inc., South San Francisco, California, USA

Correspondence: Napoleone Ferrara, M.D., Genentech, Inc., One DNA Way, South San Francisco, California 94080, USA. Telephone: 650-225-2968; Fax: 650-225-6443; e-mail: nf{at}gene.com

The development of a vascular supply is a critical factor in the growth and metastatic spread of malignant tumors. Of the multitude of growth factors that regulate physiological and pathological angiogenesis, vascular endothelial growth factor (VEGF) is believed to be the most important. There is evidence that overexpression of VEGF is correlated with an adverse prognosis, at least in some tumors. Tumor-expressed VEGF is particularly attractive as a target for anticancer therapy because its angiogenesis-promoting activity is at the level of the endothelial cell and, compared with agents that directly target tumor cells, tumor penetration is less critical for VEGF inhibitors. Moreover, recent work has shown that inhibiting tumor angiogenesis increases the effectiveness of coadministered chemotherapy and radiotherapy. This suggests that drugs that target VEGF or its receptors can be combined with traditional treatment modalities to ensure maximum effectiveness. A variety of agents aimed at blocking VEGF or its receptor-signaling system are currently being developed for the treatment of cancer. Of these, bevacizumab, a humanized monoclonal antibody directed at VEGF, is the most advanced in clinical development and has shown promising results in clinical trials.

Key Words. Vascular endothelial growth factor • Angiogenesis • Cancer • Monoclonal antibody • Bevacizumab

This article has been cited by other articles:

				M. Damianovich, M. Blank, A. Raiter, B. Hardy, and Y. Shoenfeld Anti-vascular endothelial growth factor (VEGF) specific activity of intravenous immunoglobulin (IVIg) Int. Immunol., September 1, 2009; 21(9): 1057 - 1063. [Abstract] [Full Text] [PDF]

				C. C. Milsom, J. L. Yu, N. Mackman, J. Micallef, G. M. Anderson, A. Guha, and J. W. Rak Tissue Factor Regulation by Epidermal Growth Factor Receptor and Epithelial-to-Mesenchymal Transitions: Effect on Tumor Initiation and Angiogenesis Cancer Res., December 15, 2008; 68(24): 10068 - 10076. [Abstract] [Full Text] [PDF]

				M. Aleku, P. Schulz, O. Keil, A. Santel, U. Schaeper, B. Dieckhoff, O. Janke, J. Endruschat, B. Durieux, N. Roder, et al. Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Cancer Res., December 1, 2008; 68(23): 9788 - 9798. [Abstract] [Full Text] [PDF]

				E. L. Bradshaw-Pierce, C. A. Steinhauer, D. Raben, and D. L. Gustafson Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma Mol. Cancer Ther., September 1, 2008; 7(9): 3006 - 3017. [Abstract] [Full Text] [PDF]

				C. A. Heckman, T. Holopainen, M. Wirzenius, S. Keskitalo, M. Jeltsch, S. Yla-Herttuala, S. R. Wedge, J. M. Jurgensmeier, and K. Alitalo The Tyrosine Kinase Inhibitor Cediranib Blocks Ligand-Induced Vascular Endothelial Growth Factor Receptor-3 Activity and Lymphangiogenesis Cancer Res., June 15, 2008; 68(12): 4754 - 4762. [Abstract] [Full Text] [PDF]

				S. E. Strome, E. A. Sausville, and D. Mann A Mechanistic Perspective of Monoclonal Antibodies in Cancer Therapy Beyond Target-Related Effects Oncologist, September 1, 2007; 12(9): 1084 - 1095. [Abstract] [Full Text] [PDF]

				Z. Zhou, M. F. Bolontrade, K. Reddy, X. Duan, H. Guan, L. Yu, D. J. Hicklin, and E. S. Kleinerman Suppression of Ewing's Sarcoma Tumor Growth, Tumor Vessel Formation, and Vasculogenesis Following Anti Vascular Endothelial Growth Factor Receptor-2 Therapy Clin. Cancer Res., August 15, 2007; 13(16): 4867 - 4873. [Abstract] [Full Text] [PDF]

				G. J. Riely and V. A. Miller Vascular Endothelial Growth Factor Trap in Non Small Cell Lung Cancer Clin. Cancer Res., August 1, 2007; 13(15): 4623s - 4627s. [Abstract] [Full Text] [PDF]

				F. Pisati, M. Belicchi, F. Acerbi, C. Marchesi, C. Giussani, M. Gavina, S. Javerzat, M. Hagedorn, G. Carrabba, V. Lucini, et al. Effect of Human Skin-Derived Stem Cells on Vessel Architecture, Tumor Growth, and Tumor Invasion in Brain Tumor Animal Models Cancer Res., April 1, 2007; 67(7): 3054 - 3063. [Abstract] [Full Text] [PDF]

				G. Giaccone The Potential of Antiangiogenic Therapy in Non-Small Cell Lung Cancer Clin. Cancer Res., April 1, 2007; 13(7): 1961 - 1970. [Abstract] [Full Text] [PDF]

				S. Senan and E. F. Smit Design of Clinical Trials of Radiation Combined with Antiangiogenic Therapy Oncologist, April 1, 2007; 12(4): 465 - 477. [Abstract] [Full Text] [PDF]

				L. Bozulic, P. J. Morin, T. Hunter, and B. A. Hemmings Meeting Report: Targeting the Kinome--20 Years of Tyrosine Kinase Inhibitor Research in Basel Sci. Signal., February 20, 2007; 2007(374): pe8 - pe8. [Abstract] [Full Text] [PDF]

				B. I. Rini Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma: Current Status and Future Directions Clin. Cancer Res., February 15, 2007; 13(4): 1098 - 1106. [Abstract] [Full Text] [PDF]

				X. Chen, J. Lin, T. Kanekura, J. Su, W. Lin, H. Xie, Y. Wu, J. Li, M. Chen, and J. Chang A Small Interfering CD147-Targeting RNA Inhibited the Proliferation, Invasiveness, and Metastatic Activity of Malignant Melanoma Cancer Res., December 1, 2006; 66(23): 11323 - 11330. [Abstract] [Full Text] [PDF]

				B. Kim, S. Suvas, P. P. Sarangi, S. Lee, R. A. Reisfeld, and B. T. Rouse Vascular Endothelial Growth Factor Receptor 2-Based DNA Immunization Delays Development of Herpetic Stromal Keratitis by Antiangiogenic Effects J. Immunol., September 15, 2006; 177(6): 4122 - 4131. [Abstract] [Full Text] [PDF]

				S M Hyder Sex-steroid regulation of vascular endothelial growth factor in breast cancer. Endocr. Relat. Cancer, September 1, 2006; 13(3): 667 - 687. [Abstract] [Full Text] [PDF]

				M Milano and O Guerin Recent advances in targeted therapies for colorectal cancer Journal of Oncology Pharmacy Practice, June 1, 2006; 12(2): 69 - 73. [Abstract] [PDF]

				M. Jeltsch, T. Karpanen, T. Strandin, K. Aho, H. Lankinen, and K. Alitalo Vascular Endothelial Growth Factor (VEGF)/VEGF-C Mosaic Molecules Reveal Specificity Determinants and Feature Novel Receptor Binding Patterns J. Biol. Chem., April 28, 2006; 281(17): 12187 - 12195. [Abstract] [Full Text] [PDF]

				M. Tzukerman, T. Rosenberg, I. Reiter, S. Ben-Eliezer, G. Denkberg, R. Coleman, Y. Reiter, and K. Skorecki The influence of a human embryonic stem cell-derived microenvironment on targeting of human solid tumor xenografts. Cancer Res., April 1, 2006; 66(7): 3792 - 3801. [Abstract] [Full Text] [PDF]

				A. K. Malik, M. E. Baldwin, F. Peale, G. Fuh, W.-C. Liang, H. Lowman, G. Meng, N. Ferrara, and H.-P. Gerber Redundant roles of VEGF-B and PlGF during selective VEGF-A blockade in mice Blood, January 15, 2006; 107(2): 550 - 557. [Abstract] [Full Text] [PDF]

				S. Van Schaeybroeck, A. Karaiskou-McCaul, D. Kelly, D. Longley, L. Galligan, E. Van Cutsem, and P. Johnston Epidermal Growth Factor Receptor Activity Determines Response of Colorectal Cancer Cells to Gefitinib Alone and in Combination with Chemotherapy Clin. Cancer Res., October 15, 2005; 11(20): 7480 - 7489. [Abstract] [Full Text] [PDF]

				Y. Yamazaki, Y. Matsunaga, Y. Nakano, and T. Morita Identification of Vascular Endothelial Growth Factor Receptor-binding Protein in the Venom of Eastern Cottonmouth: A NEW ROLE OF SNAKE VENOM MYOTOXIC LYS49-PHOSPHOLIPASE A2 J. Biol. Chem., August 26, 2005; 280(34): 29989 - 29992. [Abstract] [Full Text] [PDF]

				S. H. Lee, D. Lopes de Menezes, J. Vora, A. Harris, H. Ye, L. Nordahl, E. Garrett, E. Samara, S. L. Aukerman, A. B. Gelb, et al. In vivo Target Modulation and Biological Activity of CHIR-258, a Multitargeted Growth Factor Receptor Kinase Inhibitor, in Colon Cancer Models Clin. Cancer Res., May 15, 2005; 11(10): 3633 - 3641. [Abstract] [Full Text] [PDF]

				L. Manenti, E. Riccardi, S. Marchini, E. Naumova, I. Floriani, A. Garofalo, R. Dossi, E. Marrazzo, D. Ribatti, E. Scanziani, et al. Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy Mol. Cancer Ther., May 1, 2005; 4(5): 715 - 725. [Abstract] [Full Text] [PDF]

				S. M. Short, A. Derrien, R. P. Narsimhan, J. Lawler, D. E. Ingber, and B. R. Zetter Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by {beta}1 integrins J. Cell Biol., February 14, 2005; 168(4): 643 - 653. [Abstract] [Full Text] [PDF]

				H.-P. Gerber and N. Ferrara Pharmacology and Pharmacodynamics of Bevacizumab as Monotherapy or in Combination with Cytotoxic Therapy in Preclinical Studies Cancer Res., February 1, 2005; 65(3): 671 - 680. [Abstract] [Full Text] [PDF]

				N. H. Fernando and H. I. Hurwitz Targeted Therapy of Colorectal Cancer: Clinical Experience with Bevacizumab Oncologist, June 1, 2004; 9(suppl_1): 11 - 18. [Abstract] [Full Text] [PDF]

				R. S. Herbst and A. B. Sandler Non-Small Cell Lung Cancer and Antiangiogenic Therapy: What Can Be Expected of Bevacizumab? Oncologist, June 1, 2004; 9(suppl_1): 19 - 26. [Abstract] [Full Text] [PDF]